仙琚製藥(002332.SZ)放棄參股公司天台藥業5%股權優先受讓權
格隆匯7月28日丨仙琚製藥(002332.SZ)公佈,浙江天台藥業有限公司(以下簡稱“天台藥業”)系公司的參股公司,公司持有其20%的股權。公司於2020年7月22日收到天台藥業關於股權轉讓的通知,天台藥業股東成都匯信醫藥有限公司(以下簡稱“成都匯信”)持有天台藥業註冊資本261.25萬元人民幣(對應5%的股權),成都匯信擬以1750萬元人民幣的轉讓價格,將其所持有的天台藥業註冊資本261.25萬元人民幣(對應5%的股權)轉讓給自然人王寶軍。針對以上股東的股權轉讓,公司結合實際經營情況,擬放棄上述股權轉讓的優先受讓權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.